All In Biotech

Drug Trial Radar · NCT00276640

Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas

Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma

Last checked: Nov 19, 2026Latest source record: Apr 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

3,417

Actual

Start

Apr 1, 2004

Primary completion

Dec 31, 2015

Study completion May 31, 2017

Sponsor

Lead sponsor
Societe Internationale d'Oncologie PediatriqueAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 day, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying giving radiation therapy or combination chemotherapy to see how well it works in treating patients with clinically or radiologically progressive low-grade gliomas.

Conditions

  • Primary Central Nervous System Neoplasms

Interventions

  • vincristine, carboplatinDrug

    vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21 carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21

  • vincristine, carboplatin, etoposideDrug

    vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21 carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21 etoposide: 100 mg/m² i.v., week 1,4,7,10

  • radiation therapyRadiation

    intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: week 24, and at 1, 3, and 5 years
  2. Event-free survivalTime frame: week 24 and at 1, 3, and 5 years
  3. Overall survivalTime frame: week 24 and at 1, 3, and 5 years

Locations

13 sites in 12 countries. Site status is shown where the registry gives one.

  • Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik

    Vienna, Austria

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Children's Hospital Zagreb

    Zagreb, Croatia

  • Aalborg Hospital

    Aalborg, Denmark

  • Institut Gustave Roussy

    Villejuif, France

  • Klinikum Augsburg

    Augsburg, Germany

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • University of Tromso

    Tromsø, Norway

  • Children's Memorial Health Institute

    Warsaw, Poland

  • Hospital San Joao

    Porto, Portugal

  • University Children's Hospital

    Zurich, Switzerland

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom

  • Queen's Medical Centre

    Nottingham, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.